Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: Tremfya Clears FDA; Dextenza Amendment Is Too Late; Emicizumab, Abemaciclib Filed

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

Advertisement

Related Content

2Q Pharma Results Preview: Lilly, Biogen, Amgen, GSK And Gilead
J&J's First-In-Class Tremfya Poised To Join A Crowded Psoriasis Market
Does Ocular's Latest CRL Mean A Minor Delay For Dextenza, Or A New NDA?
Phase III Updates Bode Well For Filings Of Roche's Emicizumab In Hemophilia
Pfizer's Xeljanz Is First JAK Positive In PsA But Challenges Ahead
ASCO Upsets CDK4/6 Class: Strong Data For Lilly's Abemaciclib, But Pfizer's Ibrance Disappoints
Pfizer's Xeljanz: The Slow Road To Blockbuster Status
Lilly Preps Abemaciclib To Take On Ibrance; Differentiation Still A Question
Ocular Therapeutix Gets Lead Product Back On Track
Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS121106

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel